Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selepressin in vasopressor-dependent septic shock
NL-OMON43990Phase 2Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in septic shock comparing Selepressin plus standard care with Placebo plus standard care (2 arms). Primary endpoint: Vasopressor- and mechanical ventilator-free days up to Day 30. Started Oct 2016; status: active, not recruiting.
02
Drugs
selepressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NL-OMON43990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43990.